Ascendis Pharma A/s (ASND)

$142.1

+1.93

(+1.38%)▲

Market is closed - opens 7 PM, 23 Apr 2024

Insights on Ascendis Pharma A/s

  • Increasing Revenue

    Revenue is up for the last 7 quarters, 6.16M → 137.70M (in $), with an average increase of 36.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -162.22M → -86.87M (in $), with an average increase of 86.7% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 238.3% return, outperforming this stock by 230.7%

Performance

  • $141.06
    $144.33
    $142.10
    downward going graph

    0.73%

    Downside

    Day's Volatility :2.27%

    Upside

    1.55%

    downward going graph
  • $66.03
    $161.00
    $142.10
    downward going graph

    53.53%

    Downside

    52 Weeks Volatility :58.99%

    Upside

    11.74%

    downward going graph

Returns

PeriodAscendis Pharma A/sSector (Health Care)Index (Russel 2000)
3 Months
4.1%
-0.4%
0.0%
6 Months
63.07%
9.6%
0.0%
1 Year
78.14%
3.9%
-1.3%
3 Years
7.59%
12.8%
-22.1%

Highlights

Market Capitalization
7.9B
Book Value
- $2.57
Earnings Per Share (EPS)
-9.13
Wall Street Target Price
0.34
Profit Margin
-180.51%
Operating Margin TTM
-26.59%
Return On Assets TTM
-29.73%
Return On Equity TTM
-818.43%
Revenue TTM
266.7M
Revenue Per Share TTM
4.74
Quarterly Revenue Growth YOY
501.40000000000003%
Gross Profit TTM
39.0M
EBITDA
-449.0M
Diluted Eps TTM
-9.13
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.06
EPS Estimate Next Year
-0.06
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Ascendis Pharma A/s(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
15
15
Hold
4
4
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 99.76%

Current $142.10
Target $0.34

Company Financials

FY18Y/Y Change
Revenue
12.1M
↑ 591.57%
Net Income
-148.8M
↑ 5.0%
Net Profit Margin
-1.2K%
↑ 6868.31%
FY19Y/Y Change
Revenue
15.0M
↑ 26.41%
Net Income
-244.2M
↑ 67.58%
Net Profit Margin
-1.6K%
↓ 400.5%
FY20Y/Y Change
Revenue
8.6M
↓ 48.01%
Net Income
-515.3M
↑ 92.17%
Net Profit Margin
-6.0K%
↓ 4395.5%
FY21Y/Y Change
Revenue
8.8M
↑ 11.87%
Net Income
-434.4M
↓ 8.44%
Net Profit Margin
-4.9K%
↑ 1093.97%
FY22Y/Y Change
Revenue
54.8M
↑ 557.93%
Net Income
-624.7M
↑ 52.04%
Net Profit Margin
-1.1K%
↑ 3791.93%
FY23Y/Y Change
Revenue
266.7M
↑ 421.2%
Net Income
-481.4M
↓ 17.45%
Net Profit Margin
-180.51%
↑ 959.12%
Q3 FY22Q/Q Change
Revenue
15.0M
↑ 148.21%
Net Income
-166.1M
↑ 107.77%
Net Profit Margin
-1.1K%
↑ 215.11%
Q4 FY22Q/Q Change
Revenue
24.5M
↑ 49.74%
Net Income
-222.2M
↑ 22.77%
Net Profit Margin
-905.91%
↑ 199.09%
Q1 FY23Q/Q Change
Revenue
36.6M
↑ 46.7%
Net Income
-121.0M
↓ 46.53%
Net Profit Margin
-330.21%
↑ 575.7%
Q2 FY23Q/Q Change
Revenue
51.7M
↑ 41.1%
Net Income
-132.5M
↑ 9.48%
Net Profit Margin
-256.23%
↑ 73.98%
Q3 FY23Q/Q Change
Revenue
48.0M
↑ 1.35%
Net Income
-162.2M
↑ 33.59%
Net Profit Margin
-337.73%
↓ 81.5%
Q4 FY23Q/Q Change
Revenue
137.7M
↑ 186.68%
Net Income
-86.9M
↓ 46.45%
Net Profit Margin
-63.09%
↑ 274.64%
FY18Y/Y Change
Total Assets
364.9M
↑ 51.18%
Total Liabilities
44.5M
↑ 63.74%
FY19Y/Y Change
Total Assets
758.1M
↑ 112.16%
Total Liabilities
89.2M
↑ 104.58%
FY20Y/Y Change
Total Assets
1.2B
↑ 44.78%
Total Liabilities
173.5M
↑ 77.2%
FY21Y/Y Change
Total Assets
1.2B
↑ 10.73%
Total Liabilities
228.0M
↑ 42.67%
FY22Y/Y Change
Total Assets
1.2B
↑ 0.44%
Total Liabilities
885.3M
↑ 310.56%
FY23Y/Y Change
Total Assets
825.6M
↓ 24.24%
Total Liabilities
971.3M
↑ 17.53%
Q3 FY22Q/Q Change
Total Assets
1.3B
↓ 4.03%
Total Liabilities
807.9M
↑ 14.31%
Q4 FY22Q/Q Change
Total Assets
1.2B
↓ 14.42%
Total Liabilities
885.3M
↑ 0.55%
Q1 FY23Q/Q Change
Total Assets
1.1B
↓ 11.33%
Total Liabilities
871.4M
↓ 3.31%
Q2 FY23Q/Q Change
Total Assets
898.9M
↓ 14.74%
Total Liabilities
828.1M
↓ 5.02%
Q3 FY23Q/Q Change
Total Assets
873.2M
↑ 6.0%
Total Liabilities
946.6M
↑ 24.73%
Q4 FY23Q/Q Change
Total Assets
825.6M
↓ 5.45%
Total Liabilities
971.3M
↑ 2.6%
FY18Y/Y Change
Operating Cash Flow
-158.8M
↑ 45.96%
Investing Cash Flow
-3.0M
↑ 181.4%
Financing Cash Flow
232.5M
↑ 62.98%
FY19Y/Y Change
Operating Cash Flow
-197.1M
↑ 26.75%
Investing Cash Flow
-5.8M
↑ 94.83%
Financing Cash Flow
552.9M
↑ 142.83%
FY20Y/Y Change
Operating Cash Flow
-334.0M
↑ 54.34%
Investing Cash Flow
-358.2M
↑ 5544.49%
Financing Cash Flow
741.3M
↑ 22.09%
FY21Y/Y Change
Operating Cash Flow
-473.0M
↑ 53.8%
Investing Cash Flow
-125.2M
↓ 62.03%
Financing Cash Flow
397.9M
↓ 41.69%
FY22Y/Y Change
Operating Cash Flow
-531.0M
↑ 18.69%
Investing Cash Flow
66.1M
↓ 155.83%
Financing Cash Flow
425.0M
↑ 12.92%
Q3 FY22Q/Q Change
Operating Cash Flow
-97.2M
↓ 20.55%
Investing Cash Flow
13.9M
↑ 42.59%
Financing Cash Flow
-74.7K
↓ 96.6%
Q4 FY22Q/Q Change
Operating Cash Flow
-151.8M
↑ 43.36%
Investing Cash Flow
-853.8K
↓ 105.65%
Financing Cash Flow
1.4M
↓ 1875.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-160.4M
↑ 3.78%
Investing Cash Flow
51.2M
↓ 5991.72%
Financing Cash Flow
-765.5K
↓ 152.04%
Q2 FY23Q/Q Change
Operating Cash Flow
-167.1M
↑ 4.14%
Investing Cash Flow
51.2M
↑ 0.0%
Financing Cash Flow
-2.5M
↑ 228.92%
Q3 FY23Q/Q Change
Operating Cash Flow
-124.7M
↓ 18.55%
Investing Cash Flow
22.2M
↓ 52.68%
Financing Cash Flow
143.4M
↓ 6308.66%

Technicals Summary

Sell

Neutral

Buy

Ascendis Pharma A/s is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ascendis Pharma A/s
Ascendis Pharma A/s
-1.63%
63.07%
78.14%
7.59%
26.74%
Moderna, Inc.
Moderna, Inc.
-5.36%
32.83%
-24.38%
-39.84%
322.91%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.34%
13.15%
12.94%
84.22%
161.57%
Novo Nordisk A/s
Novo Nordisk A/s
-2.94%
28.97%
46.95%
238.27%
414.84%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.87%
8.77%
20.15%
83.53%
128.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ascendis Pharma A/s
Ascendis Pharma A/s
NA
NA
NA
-0.06
-8.18
-0.3
NA
-2.57
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.77
25.77
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.13
46.13
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.39
28.39
0.53
16.72
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ascendis Pharma A/s
Ascendis Pharma A/s
Buy
$7.9B
26.74%
NA
-180.51%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
322.91%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.4B
161.57%
25.77
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.3B
414.84%
46.13
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
128.04%
28.39
36.68%

Institutional Holdings

  • RA Capital Management, LLC

    17.85%

  • Artisan Partners Limited Partnership

    10.16%

  • FMR Inc

    9.03%

  • Westfield Capital Management Company, LP

    7.12%

  • HHG PLC

    7.06%

  • T. Rowe Price Investment Management,Inc.

    7.05%

Corporate Announcements

  • Ascendis Pharma A/s Earnings

    Ascendis Pharma A/s’s price-to-earnings ratio stands at None

    Read More

Company Information

ascendis pharma a/s is a biotechnology company located in 12 tuborg blvd., hellerup, capital region of denmark, denmark.

Organization
Ascendis Pharma A/s
Employees
879
CEO
Mr. Jan Moller Mikkelsen
Industry
Health Technology

Discover More

FAQs